PUBLICATION BY MATTHIAS MAGOOLA, CHEMIST

Alzheimer’s disease (AD) remains a significant challenge in the field of neurodegenerative 10 disorders, even nearly a century after its discovery, due to the elusive nature of its causes. The de- 11 velopment of drugs that target multiple aspects of the disease has emerged as a promising strategy 12 to address the complexities of AD and related conditions.

The role of the immune system, particu- 13 larly in AD, has gained considerable interest, with nanobodies representing a new frontier in bio- 14 medical research. Advances in targeting antibodies against amyloid-β (Aβ) and the use of messen- 15 ger RNA for genetic translation have revolutionized the production of antibodies and drug devel- 16 opment, opening new possibilities for treatment.

Despite these advancements, conventional treat- 17 ments for AD, such as Cognex, Exelon, Razadyne, and Aricept, often have limited long-term effec- 18 tiveness, underscoring the need for innovative solutions.

This necessity has led to the incorporation 19 of advanced technologies like artificial intelligence and machine learning into the drug discovery 20 process for neurodegenerative diseases.

These technologies not only help identify therapeutic tar- 21 gets but also optimize lead compounds, offering a more effective approach to addressing the chal- 22 lenges of AD and similar conditions.